20.09.17
We are pleased to inform you about an opportunity to share your story of living with Niemann-Pick Type C (NPC) in a market research study. An independent market research organisation, Magnolia Innovation, is currently conducting research with people, or parents of children, who have NP-C.
Read more18.09.17
The preliminary programme for this year's Annual Family Conference & Interactive Workshop is finally here - we are excited to once again welcome our community to the biggest event in the NPUK calendar!
Read more07.09.17
IntraBio announces plans for a multi-national randomised clinical trial to evaluate IB1000 as a therapeutic intervention for patients with NP-C...
Read more10.07.17
Take on the challenge of a lifetime from 10,000 ft! Enjoy the exhilarating and unforgettable feeling of a skydive - flying through the clouds from over 10, 000 ft at up to 120 mph! Niemann-Pick UK are looking for thrill-seeking fundraisers to take on this once in a lifetime challenge and if you raise enough sponsorship, you can jump for free! You will be strapped to your qualified British Parachute Association tandem instructor who does all the hard work for you, leaving you to enjoy the invigorating feeling of freefalling before gliding to the ground!
Read more18.05.17
CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will host a webinar to provide details of the Company’s recently initiated Phase I clinical trial in the U.S. and Phase I/II clinical trial in the EU, both evaluating CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C (NPC). NPC is a rare and fatal genetic disease that damages the brain, lung, liver, spleen, and other organs.
Read more
